Navigation Links
"O-Shot™" May Improve Female Sexual Response
Date:1/17/2012

LA JOLLA, Calif., Jan. 17, 2012 /PRNewswire/ -- Using growth factors derived from a woman's own blood, physician researchers Drs. Samuel Wood and Charles Runels have developed a simple, office-based procedure that appears to markedly improve the quality of a woman's sexual response. The preliminary results of this procedure, which involves the injection of platelet-derived growth factors (PDGFs) into a specific area on the upper wall of the vagina and the clitoris, were recently presented at the annual meeting of the A4M, the largest regenerative biomedicine convention in the country.

"The most important factor in the success of this procedure is the correct placement of the injections. When these same growth factors were injected into the putative 'G-Spot,' we saw minimal or no improvement in sexual function, but when injected into an area distinct from the traditionally defined G-Spot, the response has been surprising, robust and consistent," said Dr. Wood.

"This area of responsiveness is distinct enough from the ill-defined 'G-Spot' that we felt it deserved its own name. The name we chose is the 'O-Spot' ("Orgasm Spot™') and we have termed the procedure involving the injection of growth factors into this area the 'O-Shot' (Orgasm Shot). This area appears to be critical in determining whether a woman is able to achieve a vaginal orgasm, something experienced consistently by fewer than 20% of women," explained Dr. Runels.

"It is important to note that there are many potential causes of sexual dysfunction, which affects an estimated 40% of all women, and so all patients should receive a complete evaluation prior to receiving this or any other treatment. Based on over 20 years of research on the use of PDGFs for other medical conditions, the administration of PDGFs appear to safe, and with the use of a local anesthetic the O-Shot itself is associated with minimal discomfort. But because it has not been yet been studied in a comprehensive way, all women should undergo this procedure only as part of a clinical research trial." noted Dr. Wood.

"We recognize that this data is preliminary and must be confirmed by rigorous scientific research before making it widely available to patients. We are now initiating a multicenter clinical trial to definitively examine the effectiveness of this procedure. We are currently adding additional collaborating physicians to the study and are open to considering other candidates. Acceptance criteria include having an excellent understanding of female anatomy, being highly skilled at performing precise medical procedures and having an outstanding reputation among their peers," said Dr. Benito Villanueva, Medical Director at La Jolla Centre for Sexual Health and O-Shot™ Director of Physician Training.

The O-Shot is one of several procedures that involve using platelet-derived growth factors to non-invasively treat common medical problems. The first such procedure was the "Vampire Facelift," which has been featured in numerous diverse media outlets including the New York Times, and the television shows "Dr. Oz" and "The Doctors."

Samuel Wood, M.A., M.D., Ph.D., M.B.A. is a renowned reproductive endocrinologist and stem cell scientist. He is the medical director of Reproductive Sciences Center and the Scientific Director at La Jolla Centre for Sexual Health. He has been featured in numerous print and broadcast media stories and is a listee in Marquis "Who's Who in America" and "Who's Who in the World."

Charles Runels, M.D. is a cosmetic physician, best-selling author and the inventor of several PDGF-based therapies including the "Vampire Facelift."

Benito Villanueva, M.D., has been practicing medicine for over 20 years and has developed a sterling reputation in the field of sexual health and treatment. He is the Medical Director of La Jolla Centre for Sexual Health.

For additional information, visit www.oshot.info, www.lajollasexualhealth.com or call Vince Heald or Katie Woolway of Beck Ellman Heald at 858-453-9600.


'/>"/>
SOURCE Samuel Wood, M.D.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Self-assembling polymer arrays improve data storage potential
2. Beaumont Doctors Invention Improves Cataract Surgery Outcomes
3. Early-Bird Registration Ends this Week for 10th Annual Quality Excellence Conference: How Process Improvement Leaders Produce Profits in Recessions
4. Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure
5. Germicidal UVC Lights Improve Clinical Pregnancy Rates for IVF Lab, New Study Finds
6. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
7. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
8. Global Psychiatrists Unite to Improve Services in Mental Health
9. Kelly Osbourne and International Health Groups Call for Improved Education on Choices and Usage of Contraception
10. Commonwealth Care Alliance Selects Casenet To Unify Patient Information and Improve Care for Massachusetts Members
11. Finesse Solutions Launches Improved E-Store for Sensors and Transmitters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... BOSTON , Jan. 20, 2017 ... acquisition of Gen9, a pioneer in the synthesis ... Gen9,s unique expertise in assembling pathway-length synthetic DNA ... speed and capacity in the construction of new ... of industries. "Gen9 was founded to ...
(Date:1/19/2017)... and HOUSTON , Jan. ... Prenatal") today announced the formation of its Medical/Clinical ... clinicians and industry veterans who enhance the range ... it accelerates development of its novel prenatal diagnostic ... medical, clinical and strategic guidance for the company,s ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
(Date:1/19/2017)... ... 19, 2017 , ... FireflySci Inc. is a go-getter type of company that ... accounted to two main factors. The first is the amazing customer service that ... FireflySci products all around the world. , 2016 was a tremendous sales year for ...
Breaking Biology Technology:
(Date:1/12/2017)... YORK , Jan. 12, 2017  New research undertaken ... the office of the future.  1,000 participants were simply asked ... three months which we may consider standard issue.  Insights on ... of 2017 were also gathered from futurists and industry leaders ... Dr. James Canton .  Some of ...
(Date:1/6/2017)... 6, 2017  Privately-held CalciMedica, Inc., announced that ... volunteers of a novel calcium release-activated calcium (CRAC) ... Acute pancreatitis, sudden painful inflammation ... but can be very serious.  In severe cases it ... extended hospital stays, time in the ICU and ...
(Date:1/4/2017)... 4, 2017  CES 2017 – Valencell , ... today announced the launch of two new versions ... highly-accurate biometric sensor modules that incorporate the best ... and expertise. The two new designs include Benchmark ... hearables, and Benchmark BW2.0, a 2-LED version of ...
Breaking Biology News(10 mins):